AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie lupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2021
192
Period ended Dec 31, 2021
Change on a year earlier
+6.1%
181 in Q4 2020
History
20 quarters
Since Q1 2017
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 192 | +6.1% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 180 | +35.3% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 198 | -3.4% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 213 | -8.6% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 181 | -17.4% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 133 | -42.2% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 205 | -1.9% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 233 | +1.7% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 219 | -7.2% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 230 | +7.5% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 209 | -6.3% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 229 | +4.6% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 236 | +5.4% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 214 | +6.5% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 223 | +6.2% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 219 | +12.9% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 224 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 201 | – | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 210 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 194 | – | Form 10-Q (filed 2018-05-04) ↗ |
Breakdown
What makes up lupron (leuprolide) [legacy through fy21] — worldwide net revenues ($m)
- Lupron (leuprolide) [legacy through FY21] — U.S. net revenues ($M)148 · Q4 2021
- Lupron (leuprolide) [legacy through FY21] — International net revenues ($M)44 · Q4 2021
- Lupron (leuprolide) [legacy through FY21] — Worldwide reported growth YoY (%)6.0% · Q4 2021
- Lupron (leuprolide) [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%)6.0% · Q4 2021
Cite this data
StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] — Worldwide net revenues ($M) ($M), quarterly Q1 2017–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.